Skip to main content
. Author manuscript; available in PMC: 2012 Mar 21.
Published in final edited form as: Int J Oncol. 2011 Jan 21;38(4):1129–1135. doi: 10.3892/ijo.2011.918

Figure 4.

Figure 4

Promoter hypermethylation downregulates expression of HSPB2 in ESCC cell lines. (A) RT-PCR analysis for HSPB2 expression in cell lines and tissues. GAPDH was used as a loading control. L, 1 kb Plus DNA ladder. (B) Reactivation of HSPB2 by 5 µM 5-Aza-dC and/or TSA treatment. m, mock treatment; a, 5-Aza-dC treatment; a+T, 5-Aza-dC + TSA treatment. (C) HSPB2 expression in a pair of PN and PT cDNA prepared from an ESCC patient by real-time PCR. (D) HSPB2 expression in patients with ESCC (T) or without cancer (NN) by real-time PCR. Relative expression (fold) was calculated by comparing the ratios of mRNA expression of HSPB2 to an internal control gene, GAPDH. Experiments were done in duplicate, and values indicate the means ± SD. *P<0.05 (t-test).